2023-11-20 13:46:44
The High Authority for Health (HAS) has put online a “Proper use of medicines” sheet dedicated to the treatment of severe asthma: Dupicent (dupilumab), Fasenra (benralizumab), Nucala (mepolizumab), Tezspire (tezepelumab) and Xolair (omalizumab).
These monoclonal antibodies are used only following failure of a basic treatment combining at least one high-dose inhaled corticosteroid (ICS) and an inhaled beta-2 agonist (LABA), always in combination with this basic treatment.
The HAS recalls the particular indications and dispensing rules for each medication (age, eosinophil level, IgE dependence, specialists authorized to prescribe, etc.) and suggests decision trees for the management of severe uncontrolled asthma in children. adults and adolescents from 12 years old, as well as children from 6 to 11 years old.
1700490735
#Treatments #severe #asthma #develops #sheet #proper #News
